Alisertib(Alisertib) - 药物靶点：Aurora A_在研适应症：复发性乳腺癌，HR阳性/HER2阴性乳腺癌，广泛期小细胞肺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Alisertib (USAN)、Alisertib Sodium、Alsertib

+ [1]

靶点

Aurora A

作用机制

Aurora A抑制剂(丝氨酸/苏氨酸蛋白激酶Aurora-A抑制剂)

治疗领域

肿瘤呼吸系统疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

复发性乳腺癌HR阳性/HER2阴性乳腺癌广泛期小细胞肺癌+ [5]

非在研适应症

腺泡细胞癌急性髓性白血病前列腺腺癌+ [58]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Millennium Pharmaceuticals, Inc.US Oncology Research LLCTakeda Pharmaceuticals U.S.A., Inc.

+ [1]

非在研机构

Takeda Pharmaceutical Co., Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C27H20ClFN4O4

InChIKeyZLHFILGSQDJULK-UHFFFAOYSA-N

CAS号1028486-01-2

关联

70

项与 Alisertib 相关的临床试验

NCT06369285 / Recruiting临床2期

A Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.

开始日期2024-12-31

申办/合作机构

Puma Biotechnology, Inc.

NCT06095505 / Recruiting临床2期

A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.

开始日期2024-02-08

申办/合作机构

Puma Biotechnology, Inc.

NCT04555837 / Active, not recruiting临床1/2期IIT

A Phase I-II, Open Label Study Evaluating the Safety and Efficacy of Alisertib and Pembrolizumab in Patients With Rb-Deficient Head and Neck Squamous Cell Carcinomas

This phase I/II trial investigates the best dose and effect of alisertib in combination with pembrolizumab in treating patients with Rb-deficient head and neck squamous cell cancer. Alisertib may help block the growth of cancer.. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving alisertib in combination with pembrolizumab may help control Rb-deficient head and neck squamous cell cancer. HPV positive head and neck cancers are Rb-deficient.

开始日期2020-09-15

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与 Alisertib 相关的临床结果

登录后查看更多信息

100 项与 Alisertib 相关的转化医学

登录后查看更多信息

100 项与 Alisertib 相关的专利（医药）

登录后查看更多信息

325

项与 Alisertib 相关的文献（医药）

2024-09-01·NEOPLASIA

Aurkin-A, a TPX2-Aurora A small molecule inhibitor disrupts Alisertib-induced polyploidy in aggressive diffuse large B cell lymphoma

Article

作者: Dao, Jonathan ; Kovalskyy, Dmytro ; Mahadevan, Daruka ; Dray, Eloise ; Conway, Patrick J ; Montagnino, Sebastian ; De La Peña Avalos, Bárbara

Chemotherapy induced polyploidy is a mechanism of inherited drug resistance resulting in an aggressive disease course in cancer patients. Alisertib, an Aurora Kinase A (AK-A) ATP site inhibitor, induces cell cycle disruption resulting in polyaneuploidy in Diffuse Large B Cell Lymphoma (DLBCL). Propidium iodide flow cytometry was utilized to quantify alisertib induced polyploidy in U2932 and VAL cell lines. In U2932 cells, 1µM alisertib generated 8n+ polyploidy in 48% of the total cell population after 5 days of treatment. Combination of Aurkin A an AK-A/TPX2 site inhibitor, plus alisertib disrupted alisertib induced polyploidy in a dose-dependent manner with associated increased apoptosis. We generated a stable FUCCI U2932 cell line expressing Geminin-clover (S/G₂/M) and cdt1-mKO (G₁), to monitor cell cycle progression. Using this system, we identified alisertib induces polyploidy through endomitosis, which was eliminated with Aurkin A treatment. In a VAL mouse xenograft model, we show polyploidy generation in alisertib treated mice versus vehicle control or Aurkin A. Aurkin A plus alisertib significantly reduced polyploidy to vehicle control levels. Our in vitro and in vivo studies show that Aurkin A synergizes with alisertib and significantly decreases the alisertib dose needed to disrupt polyploidy while increasing apoptosis in DLBCL cells.

2024-07-01·Translational oncology

Aurora kinase A inhibition plus Tumor Treating Fields suppress glioma cell proliferation in a cilium-independent manner

Article

作者: Tian, Jia ; Shi, Ping ; Mallinger, Julianne C ; Ling, Dahao ; Khoshbouei, Habibeh ; Deleyrolle, Loic P ; Sarkisian, Matthew R ; Lin, Min

Tumor Treating Fields (TTFields) extend the survival of glioblastoma (GBM) patients by interfering with a broad range of tumor cellular processes. Among these, TTFields disrupt primary cilia stability on GBM cells. Here we asked if concomitant treatment of TTFields with other agents that interfere with GBM ciliogenesis further suppress GBM cell proliferation in vitro. Aurora kinase A (AURKA) promotes both cilia disassembly and GBM growth. Inhibitors of AURKA, such as Alisertib, inhibit cilia disassembly and increase ciliary frequency in various cell types. However, we found that Alisertib treatment significantly reduced GBM cilia frequency in gliomaspheres across multiple patient derived cell lines, and in patient biopsies treated ex vivo. This effect appeared glioma cell-specific as it did not reduce normal neuronal or glial cilia frequencies. Alisertib-mediated depletion of glioma cilia appears specific to AURKA and not AURKB inhibition, and attributable in part to autophagy pathway activation. Treatment of two different GBM patient-derived cell lines with TTFields and Alisertib resulted in a significant reduction in cell proliferation compared to either treatment alone. However, this effect was not cilia-dependent as the combined treatment reduced proliferation in cilia-depleted cell lines lacking, ARL13B, or U87MG cells which are naturally devoid of ARL13B⁺ cilia. Thus, Alisertib-mediated effects on glioma cilia may be a useful biomarker of drug efficacy within tumor tissue. Considering Alisertib can cross the blood brain barrier and inhibit intracranial growth, our data warrant future studies to explore whether concomitant Alisertib and TTFields exposure prolongs survival of brain tumor-bearing animals in vivo.

2024-05-08·Cancer research communications

Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non–small Cell Lung Cancers

Article

作者: Golemis, Erica A. ; Bagnyukova, Tetyana ; Egleston, Brian L. ; Pavlov, Valerii A. ; Serebriiskii, Ilya G. ; Borghaei, Hossein

Abstract:

The most common oncogenic driver mutations for non–small cell lung cancer (NSCLC) activate EGFR or KRAS. Clinical trials exploring treatments for EGFR- or KRAS-mutated (EGFRmut or KRASmut) cancers have focused on small-molecule inhibitors targeting the driver mutations. Typically, these inhibitors perform more effectively based on combination with either chemotherapies, or other targeted therapies. For EGFRmut NSCLC, a combination of inhibitors of EGFR and Aurora-A kinase (AURKA), an oncogene commonly overexpressed in solid tumors, has shown promising activity in clinical trials. Interestingly, a number of recent studies have indicated that EGFR activity supports overall viability of tumors lacking EGFR mutations, and AURKA expression is abundant in KRASmut cell lines. In this study, we have evaluated dual inhibition of EGFR and AURKA in KRASmut NSCLC models. These data demonstrate synergy between the EGFR inhibitor erlotinib and the AURKA inhibitor alisertib in reducing cell viability and clonogenic capacity in vitro, associated with reduced activity of EGFR pathway effectors, accumulation of enhanced aneuploid cell populations, and elevated cell death. Importantly, the erlotinib-alisertib combination also synergistically reduces xenograft growth in vivo. Analysis of signaling pathways demonstrated that the combination of erlotinib and alisertib was more effective than single-agent treatments at reducing activity of EGFR and pathway effectors following either brief or extended administration of the drugs. In sum, this study indicates value of inhibiting EGFR in KRASmut NSCLC, and suggests the specific value of dual inhibition of AURKA and EGFR in these tumors.

Significance::

The introduction of specific KRAS G12C inhibitors to the clinical practice in lung cancer has opened up opportunities that did not exist before. However, G12C alterations are only a subtype of all KRAS mutations observed. Given the high expression of AURKA in KRASmut NSCLC, our study could point to a potential therapeutic option for this subgroup of patients.

66

项与 Alisertib 相关的新闻（医药）

2024-11-05

·Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--( BUSINESS WIRE )--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 5,625 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, November 1, 2024, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer.

上市批准引进/卖出临床2期

2024-10-24

·BioSpace

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at . A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung 1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. Further information about Puma Biotechnology may be found at . Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 info@pumabiotechnology.com ir@pumabiotechnology.com David Schull or Olipriya Das, Russo Partners, +1 212 845 4200 david.schull@russopartnersllc.com olipriya.das@russopartnersllc.com

上市批准引进/卖出临床2期临床1期财报

2024-09-29

·精准药物

一类Aurora A-TPX2 PPI 抑制剂的发现

Aurora A是一种丝氨酸/苏氨酸蛋白激酶，在有丝分裂的早期阶段起重要作用；同时也是一个研究比较多的抗肿瘤靶点。目前报道有很多ATP口袋的竞争性激酶抑制剂 (如下图第一个)，但选择性可能会是挑战。 Aurora A与其它蛋白如TPX2、N-Myc互作发挥作用，因此破坏相应的PPI也是一种途径，而且可以期待选择性会好得多。但PPI抑制剂的研发一般认为挑战比较大。这里报道了一类Aurora A-TPX2的PPI抑制剂，并且展现出体内活性。其实在这之前，已经有这类小分子报道 (下图最后一个)，但也来自同一机构。这里主要看一个PPI抑制剂的案例，从筛选hit到优化为有体内药效的分子。PPI抑制剂也有难有易，但总体来说挑战比较大；这里这个例子看起来不算很挑战，但也不easy。分子hit是筛选来的，之前他们是用了HTS筛选了1万7 rationally selected compounds (focused library?)，这篇文章他们筛选了600个fragments，规模都不大。筛选离不开assay。fragment筛选他们用的是先TSA后ligand-based NMR，后面竞争性FP assay、co-crystal、ITC。最开始的fragment hit表现不出FP活性，也拿不到共晶。围绕hit做了简单修饰后，得到的fragment如分子2可以测得63μM活性，并拿到共晶。之后基于结构设计，逐步优化活性，最终得到后面做体内药效的分子CAM2602。其中一些SAR也比较有意思，感兴趣可以结合结构看一下。比如分子3到4，一个甲基提高了8x，文章提到这是一个rational design，通过减小羧基twist的能量penalty来提高活性。从分子2到3更是提高了50x，这里有两处改动，吲哚替换苯酚保留了氢键引入了疏水作用，右侧苯环取代的替换引起了临近Arg侧链翻转与苯环作用。总的来说是一个多重作用的结果。后面通过bioisostere替换羧酸并取得成功；之后右侧苯环引入新的取代，杂环与临近残基形成stacking及氢键，最终得到后面做药效的分子CAM2602。结合模式如下图A-C所示。正如可以预期的，这类分子表现出了非常好的激酶选择性。同时对Aurora B也有不错的选择性，如分子9可以达到1000x以上，与之前报道的选择性最好的Aurora A抑制剂相当或更好 (ATP口袋也有做到选择性上千倍的)。下图G是从结构分析对Aurora B选择性的原因。最后，in vitro及in vivo，PK and PD。总的来说CAM2602表现出良好的成药性，并展现出dose-dependent药效，虽然不及上临床的ATP口袋分子Alisertib。总的来说提供了一个PPI抑制剂从hit identification到优化至lead的案例，其中一些SAR也比较有意思。最后，如果回过头看比较早就已公布的Aurora A-TPX2肽段的复合物结构，有可能根据它就能锁定现在小分子结合的这个口袋，并评估其有一定的成药性，甚至可能in silico找到hit，virtual screening或基于structure-based modeling的design。maybe) Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents, J Med Chem, 2024 声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

AACR会议临床1期临床终止临床结果

100 项与 Alisertib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10085	Alisertib	-	DB05220

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性外周T细胞不明淋巴瘤	临床3期	美国	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	澳大利亚	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	奥地利	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	白俄罗斯	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	比利时	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	巴西	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	保加利亚	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	加拿大	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	智利	Millennium Pharmaceuticals, Inc.	2012-06-11
难治性外周T细胞不明淋巴瘤	临床3期	捷克	Millennium Pharmaceuticals, Inc.	2012-06-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02860000 (TBCRC041, CTgov)	临床2期	局部晚期乳腺癌 \| 激素难治性乳腺癌 \| 转移性乳腺癌 ... 更多	96	Laboratory Biomarker Analysis+Alisertib (Arm I (Alisertib))	壓夢製淵憲憲繭築鏇憲(顧獵網鏇襯繭繭衊憲製) = 鬱襯醖餘齋構壓齋壓醖糧觸艱餘鹹積襯觸齋構 (築襯廠築憲襯願夢艱鏇, 繭壓衊積觸壓範構壓膚 ~ 獵夢鹹製醖醖鹹夢餘繭) 更多	-	2024-10-18
				Laboratory Biomarker Analysis+Alisertib+Fulvestrant (Arm II (Alisertib, Fulvestrant))	壓夢製淵憲憲繭築鏇憲(顧獵網鏇襯繭繭衊憲製) = 淵夢鬱夢網遞廠積遞網糧觸艱餘鹹積襯觸齋構 (築襯廠築憲襯願夢艱鏇, 壓範襯積積淵選襯衊夢 ~ 襯鬱築鹹醖醖鹽壓淵餘) 更多
NCT02187991 (CTgov)	临床2期	转移性乳腺癌	169	Paclitaxel (ER+/HER2- Paclitaxel Alone)	餘範糧範膚餘衊壓鹽憲(鬱鹽糧齋憲選醖廠鬱鹽) = 蓋鬱憲鑰積顧齋觸壓鏇窪觸願製蓋鏇製繭觸襯 (糧餘醖築製壓廠淵網糧, 窪糧積餘觸繭淵窪鑰鏇 ~ 餘廠襯願繭範餘築願艱) 更多	-	2024-10-09
				Alisertib+Paclitaxel (ER+/HER2- Paclitaxel Plus Alisertib)	餘範糧範膚餘衊壓鹽憲(鬱鹽糧齋憲選醖廠鬱鹽) = 範憲壓憲艱壓憲衊窪衊窪觸願製蓋鏇製繭觸襯 (糧餘醖築製壓廠淵網糧, 鏇蓋廠憲窪獵膚壓鹽構 ~ 築鬱鬱廠製淵遞糧製製) 更多
NCT04085315 (phase I/Ib study, ASCO2024) 人工标引	临床1期	EGFR突变肺癌 EGFR	21	alisertib+osimertinib	鹹糧壓壓窪願鹹鑰齋鏇(觸壓憲艱夢製顧鏇醖顧) = neutropenia (42.9%), anemia (42.9%), and diarrhea (38.1%) 醖鬱鹽壓襯鏇鬱窪廠淵 (壓觸餘顧蓋製鬱鹽壓鹽 )	积极	2024-05-24
NCT02860000 (TBCRC041, ASCO2024)	临床2期	转移性乳腺癌 ESR1 \| PIK3CAmutation \| AKT1 ... 更多	91	Alisertib + Fulvestrant	壓鏇膚繭廠鏇鹹製顧築(蓋艱遞構襯網選膚廠齋): HR = 1.8 (95% CI, 1.1 ~ 2.9), P-Value = 0.014	积极	2024-05-24
				Alisertib
NCT02187991 (ASCO2023)	临床2期	HER2 阴性乳腺癌	96	Alisertib+Paclitaxel	餘膚獵膚鬱憲遞艱艱淵(鏇窪構襯鹹願鹹夢壓窪) = 憲鹽築廠憲衊製艱艱觸蓋製鬱築鹹積繭範壓壓 (壓積範鏇蓋壓願構餘襯 )	积极	2023-05-31
NCT02860000 (Pubmed)	临床2期	晚期乳腺癌 CDK 4/6i	91	Alisertib	製醖艱夢構鹹鹽築遞範(艱網餘鬱顧觸夢鹹範顧) = 齋膚艱廠選齋夢製積願艱壓鹽蓋觸淵鹽鏇憲簾 (積糧築齋蓋鹹淵願齋範, 29.0% ~ 54.5%) 更多	-	2023-03-09
				Alisertib + Fulvestrant	製醖艱夢構鹹鹽築遞範(艱網餘鬱顧觸夢鹹範顧) = 壓顧遞憲繭淵窪憲糧鏇艱壓鹽蓋觸淵鹽鏇憲簾 (積糧築齋蓋鹹淵願齋範, 18.0% ~ 42.0%) 更多
NCT02293005 (CTgov)	临床2期	恶性间皮瘤	28	Alisertib	顧糧製鑰鹹窪願鹽齋遞(夢鹽網獵壓糧築衊窪顧) = 鬱糧製蓋網鏇願選觸壓製鏇鬱艱壓鹽衊齋齋鏇 (積憲蓋夢淵遞製觸鑰艱, 遞夢獵艱淵廠蓋製築膚 ~ 鑰簾窪網壓鏇蓋鹽夢鹹) 更多	-	2022-10-04
NCT01924260 (Pubmed) 人工标引	临床1期	HR阳性/HER2低表达实体瘤 \| 胰腺癌	26	Alisertib+Gemcitabine	醖製膚築顧鏇遞廠選簾(網淵膚鹹鑰觸鬱鏇鏇選) = 獵築淵獵鏇構襯觸餘淵鑰壓糧構遞選壓築製鏇 (淵壓積顧網蓋蓋餘鬱顧, 2.1 ~ 4.5) 更多	积极	2022-07-30
NCT02114229 (SJATRT, Pubmed) 人工标引	临床2期	中枢神经系统横纹肌瘤	30	alisertib	選構憲構廠鏇淵簾範鹹(願鑰淵鹹鹽鬱廠願遞遞) = 網範憲糧餘醖膚憲積夢顧蓋糧廠衊壓網淵襯鑰 (願製鹹窪繭蓋鹽淵製願, 5.6) 更多	不佳	2022-06-02
NCT04479306 (ASCO2022)	临床1期	复发性非小细胞肺癌	40	Osimertinib 80 mg daily + Alisertib 20 mg, 30 mg, and 40 mg daily	(鑰簾鹽鏇積築鏇廠糧餘) = Biomarker analysis is ongoing to identify the molecular determinants of response and resistance to sapasertib 餘遞襯憲願繭淵簾遞網 (鬱鑰網淵獵鹹構壓築鹹 ) 更多	-	2022-06-02
				Osimertinib 80 mg daily + Sapanisertib 2 mg and 3 mg daily